The US Food and Drug Administration has cleared the Nexpowder endoscopic hemostasis system. Nexpowder (Medtronic) uses a noncontact, nonthermal, nontraumatic hemostatic powder that is sprayed through ...
SEOUL, South Korea, May 29, 2025 /PRNewswire/ -- Nextbiomedical announced today that its novel hemostatic powder, Nexpowder™, has been published in GUT (Impact Factor: 23), one of the world's most ...
Nexpowder is a noncontact, nonthermal and nontraumatic powder that can treat upper gastrointestinal bleeding, according to a Sept. 28 news release from the company shared with Becker’s. Seventy-five ...
Next Biomedical announced on the 17th that it has completed the first shipment of its hemostatic agent for endoscopy, Nexpowder, to Japan. Nexpowder received product approval from the Pharmaceuticals ...
LS Securities forecasted on the 22nd that sales of Nextbiomedical will rapidly increase as the market penetration rate of NexPowder rises. Jo Eun-ae, a researcher at LS Securities, explained, ...
Every year in the U.S., doctors perform more than 1 million endoscopic hemostasis procedures to treat gastrointestinal bleeding, the majority of which are upper GI bleeds. One popular treatment method ...
NextBioMedical has set a new record high since its listing on the KOSDAQ market in August last year. The company’s profitability continued through the third quarter following the second quarter this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results